392 related articles for article (PubMed ID: 17023034)
21. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Sompolska-Rzechuła AM; Tołoczko-Grabarek AI; Rzepka-Górska IA
J Ovarian Res; 2014; 7():62. PubMed ID: 25018782
[TBL] [Abstract][Full Text] [Related]
22. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
23. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.
Zanotti L; Bignotti E; Calza S; Bandiera E; Ruggeri G; Galli C; Tognon G; Ragnoli M; Romani C; Tassi RA; Caimi L; Odicino FE; Sartori E; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2012 Dec; 50(12):2189-98. PubMed ID: 23096757
[TBL] [Abstract][Full Text] [Related]
24. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
25. The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma.
Modarres-Gilani M; Vaezi M; Shariat M; Zamani N; Nourizadeh R
Cancer Biomark; 2017 Aug; 20(2):135-141. PubMed ID: 28800309
[TBL] [Abstract][Full Text] [Related]
26. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
Özdemir E; Çiçek T; Kaya MO
Urol J; 2012; 9(3):568-73. PubMed ID: 22903479
[TBL] [Abstract][Full Text] [Related]
27. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
28. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
29. YKL-40 tissue expression and plasma levels in patients with ovarian cancer.
Høgdall EV; Ringsholt M; Høgdall CK; Christensen IJ; Johansen JS; Kjaer SK; Blaakaer J; Ostenfeld-Møller L; Price PA; Christensen LH
BMC Cancer; 2009 Jan; 9():8. PubMed ID: 19134206
[TBL] [Abstract][Full Text] [Related]
30. Serum YKL-40 as a marker for cervical adenocarcinoma.
Mitsuhashi A; Matsui H; Usui H; Nagai Y; Tate S; Unno Y; Hirashiki K; Seki K; Shozu M
Ann Oncol; 2009 Jan; 20(1):71-7. PubMed ID: 18723551
[TBL] [Abstract][Full Text] [Related]
31. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
32. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
34. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
35. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.
Johansen JS; Lottenburger T; Nielsen HJ; Jensen JE; Svendsen MN; Kollerup G; Christensen IJ
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2603-8. PubMed ID: 18843001
[TBL] [Abstract][Full Text] [Related]
36. Serum tetranectin and CA125 in endometrial adenocarcinoma.
Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
[TBL] [Abstract][Full Text] [Related]
37. Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer.
Chen YL; Huang CY; Chien TY; Huang SH; Wu CJ; Ho CM
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):397-402. PubMed ID: 21806586
[TBL] [Abstract][Full Text] [Related]
38. [The importance of determining the prognostic marker YKL-40 in serum and tissues].
Łata E; Gisterek I; Matkowski R; Szelachowska J; Kornafel J
Pol Merkur Lekarski; 2010 Jun; 28(168):505-8. PubMed ID: 20642115
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer.
Bi J; Lau SH; Lv ZL; Xie D; Li W; Lai YR; Zhong JM; Wu HQ; Su Q; He YL; Zhan WH; Wen JM; Guan XY
Hum Pathol; 2009 Dec; 40(12):1790-7. PubMed ID: 19765801
[TBL] [Abstract][Full Text] [Related]
40. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]